Latest
Paralign Health Raises $3M Seed to Expand EMS-Led Preventive Care InfrastructureParalign Health Raises $3M Seed to Expand EMS-Led Preventive Care Infrastructure|Blulabs Raises $7M as Supply Chain Infrastructure Becomes Strategic PowerBlulabs Raises $7M as Supply Chain Infrastructure Becomes Strategic Power|Secretome Therapeutics Raises $30M Series A as Cell Therapy Capital Gets Selective AgainSecretome Therapeutics Raises $30M Series A as Cell Therapy Capital Gets Selective Again|Trajectory Raises $15M Seed to Build Continual Learning AI InfrastructureTrajectory Raises $15M Seed to Build Continual Learning AI Infrastructure|Rightsline Lands $500M From Hg as IP Infrastructure Becomes a Strategic BattlegroundRightsline Lands $500M From Hg as IP Infrastructure Becomes a Strategic Battleground|Amusement Connect Raises Periscope Equity Investment for Cashless Arcade SoftwareAmusement Connect Raises Periscope Equity Investment for Cashless Arcade Software|Sychedelic Raises $3.5M Seed to Push Consumer Neurotech Beyond Passive TrackingSychedelic Raises $3.5M Seed to Push Consumer Neurotech Beyond Passive Tracking|Why Whitnie Narcisse’s Networking Masterclass Matters in a Slower Startup MarketWhy Whitnie Narcisse’s Networking Masterclass Matters in a Slower Startup Market|Salesforce Connections 2026 Turns Chicago Into an AI Marketing Pressure TestSalesforce Connections 2026 Turns Chicago Into an AI Marketing Pressure Test|AWS for Startups AI Visionaries Forum Signals the Next Enterprise AI BattlegroundAWS for Startups AI Visionaries Forum Signals the Next Enterprise AI Battleground|Paralign Health Raises $3M Seed to Expand EMS-Led Preventive Care InfrastructureParalign Health Raises $3M Seed to Expand EMS-Led Preventive Care Infrastructure|Blulabs Raises $7M as Supply Chain Infrastructure Becomes Strategic PowerBlulabs Raises $7M as Supply Chain Infrastructure Becomes Strategic Power|Secretome Therapeutics Raises $30M Series A as Cell Therapy Capital Gets Selective AgainSecretome Therapeutics Raises $30M Series A as Cell Therapy Capital Gets Selective Again|Trajectory Raises $15M Seed to Build Continual Learning AI InfrastructureTrajectory Raises $15M Seed to Build Continual Learning AI Infrastructure|Rightsline Lands $500M From Hg as IP Infrastructure Becomes a Strategic BattlegroundRightsline Lands $500M From Hg as IP Infrastructure Becomes a Strategic Battleground|Amusement Connect Raises Periscope Equity Investment for Cashless Arcade SoftwareAmusement Connect Raises Periscope Equity Investment for Cashless Arcade Software|Sychedelic Raises $3.5M Seed to Push Consumer Neurotech Beyond Passive TrackingSychedelic Raises $3.5M Seed to Push Consumer Neurotech Beyond Passive Tracking|Why Whitnie Narcisse’s Networking Masterclass Matters in a Slower Startup MarketWhy Whitnie Narcisse’s Networking Masterclass Matters in a Slower Startup Market|Salesforce Connections 2026 Turns Chicago Into an AI Marketing Pressure TestSalesforce Connections 2026 Turns Chicago Into an AI Marketing Pressure Test|AWS for Startups AI Visionaries Forum Signals the Next Enterprise AI BattlegroundAWS for Startups AI Visionaries Forum Signals the Next Enterprise AI Battleground
Back to articles

Zero Shot Launches With $20M Toward a $100M Fund to Back Technically Grounded Early-Stage AI Startups

Zero Shot feels less like a name and more like a tell. No hesitation, no warm-up round, just straight to execution. The kind of move you make when you’ve already run the simulations in your head and didn’t like how slow everyone else was playing it.

Zero Shot, a venture capital fund built by OpenAI alumni, is aiming for a $100M fund and has already locked in an initial $20M. Not bad for a first verse. The founding lineup reads like a room where the conversations move faster than most markets. Evan Morikawa, who led Applied Platform Engineering at OpenAI. Andrew Mayne, OpenAI’s first prompt engineer. Shawn Jain, coming out of research with a bias toward what actually works. Kelly Kovacs bringing venture discipline. Brett Rounsaville adding operator muscle where theory meets reality.

This isn’t tourists buying into AI because it’s trending. This is builders backing builders. You can see it in the early bets and, more importantly, in what those bets ignore. Worktrace AI goes straight at enterprise workflows, the unglamorous layer where time quietly disappears and margins get chipped down without anyone filing a report about it. Foundry Robotics walks into factories, where software has to earn its keep in steel, timing, and tolerance, not slide decks. Different arenas, same thesis. Intelligence that shows up to work.

The edge here isn’t access, it’s perspective. Zero Shot isn’t trying to win by being first into a round or loudest in a thread. They’re underwriting with context most people in the room don’t have. When you’ve actually built and deployed systems at scale, you stop romanticizing potential and start interrogating reality. What breaks, where it breaks, and how expensive that failure becomes over time. That filter doesn’t just shape a portfolio, it shapes an entire category of companies that actually get a shot at existing.

And the market is quietly shifting to meet that energy. There’s less patience now for surface-level intelligence wrapped in clean UX and big claims. More scrutiny on whether the product holds up when it meets operational friction. Founders who can answer that are getting through. The rest are learning that narrative alone doesn’t clear technical gravity.

Zero Shot is leaning into that tension. Technical depth as a gatekeeper, not a bonus feature. A bias toward systems that integrate, automate, and endure rather than just impress. It’s a different cadence of investing, one that trades a little speed for a lot more signal. And in a market where everyone says they’re early, the real advantage is knowing what actually matters before it becomes obvious.